{"title":"Talquetamab (Talvey) for multiple myeloma.","authors":"","doi":"10.58347/tml.2023.1684e","DOIUrl":null,"url":null,"abstract":"Talquetamab-tgvs (Talvey – Janssen), a bispecific GPRC5D-directed T-cell engager, has been granted accelerated approval by the FDA for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Letter on Drugs and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.58347/tml.2023.1684e","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Talquetamab-tgvs (Talvey – Janssen), a bispecific GPRC5D-directed T-cell engager, has been granted accelerated approval by the FDA for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.
期刊介绍:
The Medical Letter, Inc. is committed to providing objective, practical, and timely information on drugs and treatments of common diseases to help our readers make the best decisions for their patients—without the influence of the pharmaceutical industry.
The Medical Letter On Drugs and Therapeutics is a biweekly publication that provides:
Evidence-based, peer-reviewed evaluations of new FDA-approved drugs with conclusions reached by a consensus of experts
New information on previously approved drugs including pivotal clinical trials, new indications, and safety warnings
Consensus recommendations for the preferred and alternative treatments for common disorders
Comparative reviews of drugs for a given indication with particular attention to clinical efficacy, adverse effects, drug interactions, and cost.